“GLP-1s are addictive.”
What the evidence shows
Addiction, in the medical sense, involves compulsive drug-seeking, a rewarding "high," escalating use to chase that high, and a withdrawal syndrome. GLP-1 drugs don't fit that pattern: they aren't controlled substances, they don't produce a euphoric high, and there's no recognized withdrawal syndrome when they're stopped. If anything, the mechanism runs the opposite direction — GLP-1 signaling dampens activity in the brain's reward circuits, which is exactly why these drugs are being studied to reduce cravings in alcohol and other addictions. In an early randomized trial, semaglutide reduced alcohol craving and intake.
What we still don’t know
The reward-modulating effects on cravings and "food noise" are still emerging science, and we don't fully know how durable they are or whether they persist after stopping. What's well established is what addiction is not — and ongoing treatment need for a chronic condition isn't it.
Why the claim misleads
"Addictive" misreads dependence-on-effect as dependence-on-drug. When people stop a GLP-1, appetite and weight tend to return — the same way blood pressure climbs again if you stop a blood-pressure pill. That's the underlying biology reasserting itself, not craving or withdrawal. Calling the medicine "addictive" borrows the language of opioids and misapplies it, and mostly adds stigma to a treatment for a chronic condition.
Graded by The Peptide Era · evidence, not hype